dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;IIb&beta;3

Ligand: tirofiban (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998)
Primary target: yes
Median affinity: 9.430000305175781 pIC50
Reference (Journal): Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
Published in: Eur J Med Chem

Ligand: GR 144053 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.429999828338623 pIC50
Reference (Journal): Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent.
Published in: J Med Chem

Ligand: G4120 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.
Published in: Circulation

Ligand: G4120 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
Published in: Arterioscler Thromb

Ligand: eptifibatide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998), EMA (1999)
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
Published in: J Med Chem

Ligand: abciximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (1994)
Primary target: yes
Median affinity:  -
Reference (Patent): Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3.
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;E&beta;7

Ligand: etrolizumab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.
Published in: Br J Pharmacol
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha 9 subunit

Ligand: SVEP1 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Polydom/SVEP1 is a ligand for integrin α9β1.
Published in: J Biol Chem

Ligand: BOP (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 11.520000457763672 pKd
Reference (Journal): Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1.
Published in: Biochemistry
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha 7 subunit

Ligand: etrolizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.
Published in: Br J Pharmacol
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha 5 subunit (fibronectin receptor, alpha polypeptide)

Ligand: volociximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.489999771118164 pKd
Reference (Journal): Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
Published in: Invest New Drugs

Ligand: volociximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.489999771118164 pKd
Reference (Journal): A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
Published in: J Transl Med
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;5&beta;1

Ligand: volociximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.489999771118164 pKd
Reference (Journal): Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
Published in: Invest New Drugs
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;V&beta;3

Ligand: echistatin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 11.699999809265137 pIC50
Reference (Journal): High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip.
Published in: J Biomol Screen
Target family: Integrins (type: catalytic_receptor)
Target: integrin, beta 6 subunit

Ligand: compound 7 [PMID: 31381331] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.970000267028809 pKi
Reference (Journal): Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective Methylation.
Published in: J Med Chem
Target family: Integrins (type: catalytic_receptor)
Target: integrin, beta 5 subunit

Ligand: compound 7 [PMID: 31381331] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKi
Reference (Journal): Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective Methylation.
Published in: J Med Chem
Target family: Integrins (type: catalytic_receptor)
Target: integrin, beta 3 subunit (platelet glycoprotein IIIa, antigen CD61)

Ligand: compound 7 [PMID: 31381331] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pKi
Reference (Journal): Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective Methylation.
Published in: J Med Chem
Target family: Integrins (type: catalytic_receptor)
Target: integrin, beta 2 subunit (complement component 3 receptor 3 and 4 subunit)

Ligand: rovelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia.
Published in: Exp Neurol

Ligand: rovelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Inhibition of in vivo neutrophil transmigration by a novel humanized anti-CD11/CD18 monoclonal antibody.
Published in: Cytokines Cell Mol Ther
Target family: Integrins (type: catalytic_receptor)
Target: integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)

Ligand: compound 7 [PMID: 31381331] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pKi
Reference (Journal): Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective Methylation.
Published in: J Med Chem
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha V subunit

Ligand: MK-0429 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.
Published in: J Med Chem

Ligand: GSK3008348 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.800000190734863 pKd
Reference (Journal): Characterisation of a novel, high affinity and selective &#x3b1;v&#x3b2;6 integrin RGD-mimetic radioligand.
Published in: Biochem Pharmacol

Ligand: bexotegrast (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.46999979019165 pIC50
Reference (Journal): Dual inhibition of α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> reduces fibrogenesis in lung tissue explants from patients with IPF.
Published in: Respir Res
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;V&beta;3

Ligand: TP508 (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 7.860000133514404 pKd
Reference (Journal): RGD-dependent binding of TP508 to integrin alphavbeta3 mediates cell adhesion and induction of nitric oxide.
Published in: Thromb Haemost

Ligand: P11 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 11.600000381469727 pIC50
Reference (Journal): High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip.
Published in: J Biomol Screen

Ligand: GSK2603566A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis.
Published in: J Med Chem

Ligand: etaracizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 6.340000152587891 pKd
Reference (Patent): Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity.
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;1&beta;1

Ligand: obtustatin (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.1 pIC50
Reference (Journal): Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo.
Published in: Cancer Res
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;2&beta;1

Ligand: BTT-3033 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Novel α2β1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation.
Published in: J Biol Chem

Ligand: TCI15 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.9 pIC50
Reference (Journal): Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism.
Published in: Proc Natl Acad Sci USA
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha 3 subunit (antigen CD49C, alpha 3 subunit of VLA-3 receptor)

Ligand: peptide ligand 2 [PMID: 19055415] (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.239999771118164 pIC50
Reference (Journal): Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method.
Published in: J Med Chem
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;4&beta;1

Ligand: BIO1211 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.
Published in: J Med Chem

Ligand: BOP (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 11.300000190734863 pKd
Reference (Journal): Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1.
Published in: Biochemistry

Ligand: carotegrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.239999771118164 pIC50
Reference (Patent): New phenylalanine derivatives

Ligand: firategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis.
Published in: Eur J Neurol

Ligand: natalizumab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2006)
Primary target: no
Median affinity:  -
Reference (Journal): Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Published in: Drugs R D

Ligand: TCS2314 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: valategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers.
Published in: J Clin Pharmacol

Ligand: zaurategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.
Published in: PLoS One
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;4&beta;7

Ligand: carotegrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.479999542236328 pIC50
Reference (Patent): New phenylalanine derivatives

Ligand: etrolizumab (Antibody)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 10.119999885559082 pIC50
Reference (Patent): Humanized anti-beta7 antagonists and uses therefor.

Ligand: firategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis.
Published in: Eur J Neurol

Ligand: valategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers.
Published in: J Clin Pharmacol

Ligand: vedolizumab (Antibody)
Interaction type: Antibody
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2014)
Primary target: yes
Median affinity: 8.270000457763672 pIC50
Reference (Patent): Humanized immunoglobulin reactive with &alpha;4&beta;7 integrin.

Ligand: zaurategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.
Published in: PLoS One
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor)

Ligand: abrilumab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 11.050000190734863 pKd
Reference (Journal): Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.
Published in: Br J Pharmacol

Ligand: carotegrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: firategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis.
Published in: Eur J Neurol

Ligand: natalizumab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2006)
Primary target: yes
Median affinity:  -
Reference (Journal): Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Published in: Drugs R D

Ligand: valategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers.
Published in: J Clin Pharmacol

Ligand: zaurategrast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.
Published in: PLoS One
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;5&beta;1

Ligand: volociximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.489999771118164 pKd
Reference (Journal): A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
Published in: J Transl Med
Target family: Integrins (type: catalytic_receptor)
Target: integrin, beta 8 subunit

Ligand: compound 7 [PMID: 31381331] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pKi
Reference (Journal): Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective Methylation.
Published in: J Med Chem
Target family: Interferon receptor family (type: catalytic_receptor)
Target: Interferon-&alpha;/&beta; receptor

Ligand: IFN-α4 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-α21 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-α2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1989)
Median affinity:  -

Ligand: IFN-α17 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-α16 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-α14 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Interferon receptor family (type: catalytic_receptor)
Target: Interferon-&gamma; receptor

Ligand: IFN-γ (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1999)
Median affinity:  -
Target family: Interferon receptor family (type: catalytic_receptor)
Target: Interferon-&alpha;/&beta; receptor

Ligand: IFN-α5 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: peginterferon alfa-2b (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA (2000), FDA (2001)
Primary target: yes
Median affinity:  -
Reference (Journal): The Jak-Stat pathway in normal and perturbed hematopoiesis.
Published in: Blood

Ligand: IFN-α6 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-α7 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-α8 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-β (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-κ (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Interferon receptor family (type: catalytic_receptor)
Target: interferon &alpha;/&beta;  receptor 1

Ligand: peginterferon alfa-2b (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA (2000), FDA (2001)
Primary target: yes
Median affinity:  -
Reference (Journal): The Jak-Stat pathway in normal and perturbed hematopoiesis.
Published in: Blood

Ligand: IFN-β (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pKd
Reference (Journal): A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans.
Published in: Nat Commun
Target family: Interferon receptor family (type: catalytic_receptor)
Target: Interferon-&alpha;/&beta; receptor

Ligand: IFN-α1/13 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Interferon receptor family (type: catalytic_receptor)
Target: interferon &alpha;/&beta;  receptor 1

Ligand: anifrolumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2021), EMA (2022)
Primary target: yes
Median affinity: 10 pKd
Reference (Patent): Interferon alpha receptor I antibodies and their use.
Target family: Interferon receptor family (type: catalytic_receptor)
Target: Interferon-&alpha;/&beta; receptor

Ligand: IFN-ω (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: IFN-α10 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Interleukin-1 receptor-associated kinase (IRAK) family (type: enzyme)
Target: interleukin 1 receptor associated kinase 4

Ligand: zimlovisertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.699999809265137 pIC50
Reference (Journal): Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
Published in: J Med Chem